Tele: 561.316.3330
Breaking Medical Device News

Wednesday, October 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeBioVentrixStudy Design for REVIVE-HF: RCT in Europe

Study Design for REVIVE-HF: RCT in Europe

The Revivent TC™ System has continued to deliver impressive results when evaluating post-market data in Europe.  The last 35 consecutive cases have resulted in a 34% improvement in ejection fraction (EF), 37% left ventricular volume reduction, zero deaths, and zero complications.  BioVentrix, Inc. announced today the study design for their Randomized Evaluation and Verification of Ventricular Enhancement or REVIVE-HF study to further investigate the Revivent TC System.  The trial design is based on feedback provided by the company’s Medical Advisory Board.  REVIVE-HF will investigate the efficacy of the Revivent TC System compared to Guideline Directed Medical Therapy (GDMT) for patients with left ventricular dysfunction resulting in heart failure.

REVIVE-HF is designed as a prospective, multi-center, dual-arm randomized controlled study comparing the treatment of ischemic cardiomyopathy induced heart failure with the Revivent TC System plus GDMT compared to GDMT alone.  This study will include 180 patients of which 120 patients will be treated with the Revivent TC System, and 60 patients will be maintained on GDMT. Its primary endpoint is improvement in heart failure symptoms based on a 6 Minute Walking Test. The Revivent TC System is intended for use in patients who have had a myocardial infarction (MI) (heart attack), creating a left ventricular scar, resulting in an enlarged left ventricle causing heart failure symptoms. These symptoms include fatigue, shortness of breath and/or physical limitations despite ongoing treatment.

“The prognosis for patients with heart failure, low LVEF and ischemic, dilated left ventricles is very poor and the Revivent TC System offers a realistic solution to restore the heart,” says Professor Stefan Anker, REVIVE-HF Principal Investigator. “It is critical that ventricular restoration gets more attention again, especially with the advent of this less invasive approach, and the REVIVE-HF study will provide the evidence we need for ischemic heart failure patients with reduced ejection fraction.”

BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA. Our mission is to improve and expand the treatment available for congestive heart failure (CHF) caused by ischemic cardiomyopathy, through the development of less invasive, catheter-based approaches.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

This infusion of capital will support the initiation of a first-in-human trial of ADAM™, the world’s first hydrogel implant designed to provide long-lasting, non-permanent contraception for men.

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Luciana Borio MD is a respected physician with vast experience in advancing major regulatory and policy agendas for the United States.

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

By using this website you agree to accept Medical Device News Magazine Privacy Policy